Cushing’s syndrome: drug targets and therapeutic options

Bibliography

• ORTH DN: Cushing's syndrome. New EngL J. Med. (1995) 332:791–803.
   PubMedGoogle Scholar
• DAHIA PLM, GROSSMAN A: The molecular pathogenesis of corticotroph tumours. Endocr. Rev. (1999) 20:136–155.
   PubMedGoogle Scholar
• ••Comprehensive review on molecularalterations in ACTH-secreting tumours.
   Google Scholar
• WAJCHENBERG BL, MENDONCA BB, LIBERMAN B et al.: Ectopic adrenocorticotropic hormone syndrome. Endocr. Rev. (1994) 15:752–787.
   PubMedGoogle Scholar
• BOSCARO M, BARZON L, FALLO F, SONINON: Cushing's syndrome. Lancet (2001) 357:783–791.
   PubMed Web of Science ®Google Scholar
• WAJCHENBERG BL, ALBERGARIA PEREIRA MA, MEDONCA BB et al.: Adrenocortical carcinoma: clinical and laboratory observations. Cancer (2000) 88(4):711–736.
   PubMed Web of Science ®Google Scholar
• MILLER JW CRAPO L: The medical treatment of Cushing's syndrome. Endocr. Rev. (1993) 14(4):443–458.
   PubMedGoogle Scholar
• ••Reviews all the clinical studies performed inpatients with Cushing's syndrome.
   Google Scholar
• MALLON PW, COOPER DA, CARR A: HIV-associated lipodystrophy. HIV Med. (2001) 2:166–173.
   PubMedGoogle Scholar
• GRINSPOON S: Insulin resistance in the HIV-lipodystrophy syndrome. Trends EndocrinoL Metab. (2001) 12(9):413–419.
   PubMedGoogle Scholar
• COLAO A, DI SARNO A, MARZULLO P et al.: New medical approaches in pituitary adenomas. Harm. Res. (2000) 53:76–87.
   PubMedGoogle Scholar
• ALEXANDER JM, BILLER BM, BIKKAL H, ZERVAS NT, ARNOLD A, KLIBANSKI A: Clinically non-functioning pituitary tumours are monoclonal in origin. J. Clin. Invest. (1990) 86:336–340.
   PubMed Web of Science ®Google Scholar
• CLAYTON RN, FARRELL WE: Clonality of pituitary tumours: more complicated than initially envisaged? Brain PathoL (2001) 11(3):313–327.
   PubMedGoogle Scholar
• RAY D, MELMED S: Pituitary cytokine and growth factor expression and action. Endocr. Rev. (1997) 18:206–228.
   PubMed Web of Science ®Google Scholar
• ••Review on paracrine interactions thatcontrol pituitary cell growth and hormone secretion.
   Google Scholar
• RENNER U, PAGOTTO U, ARZT E, STALLA GK: Autocrine and paracrine roles of polypeptide growth factors, cytokines and vasogenic substances in normal and tumorous pituitary function and growth: a review. Eur. EndocrinoL (1996) 135:515–532.
   PubMed Web of Science ®Google Scholar
• ARZT E, PEREDA MP, CASTRO CP, PAGOTTO U, RENNER U, STALLA GK: Pathophysiological role of the cytokine network in the anterior pituitary gland. Front. NeuroendocrinoL (1999) 20(1):71–95.
   PubMedGoogle Scholar
• REUL JM, HOLSBOER F: Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr. Opin. PharmacoL (2002) 2(1):23–33.
   PubMedGoogle Scholar
• DE KEYZER Y, RENE P, LENNE F, AUZAN C, CLAUSER E, BERTAGNA X: V3 vasopressin receptor and corticotropic phenotype in pituitary and nonpituitary tumours. Horm. Res. (1997) 47(4-6):259–262.
   PubMedGoogle Scholar
• BOUTILLIER AL, MONNIER D, LORANG D, LUNDBLAD JR, ROBERTS JL, LOEFLER JP: Corticotropin-releasing hormone stimulates proopiomelanocortin transcription by cFos-dependent and -independent pathways: characterization of an AP-1 site in exon 1. Mol. Endocrinol. (1995) 9:745–755.
   PubMed Web of Science ®Google Scholar
• AUTELITANO DJ, COHEN DR: CRF stimulates expression of multiple fos and jun related genes in the AtT-20 corticotroph cell. Mol. Cell. Endocrinol. (1999) 119:25–35.
   Google Scholar
• TIMPL P, SPANAGEL R, SILLABER I, et al.: Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor. Nat. Genet. (1998) 19(2):162–166.
   Google Scholar
• DIETERICH KD, GUNDELFINGER ED, LUDECKE DK, LEHNERT H: Mutation and expression analysis of corticotropin-releasing Factor 1 receptor in adrenocorticotropin-secreting pituitary adenomas]. Clin. Endocrinol. Metab. (1998) 83(9):3327–3331.
   Google Scholar
• BOUSQUET C, SUSINI C, MELMED S: Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor]. Clin. Invest. (1999) 104(9):1277–1285.
   Google Scholar
• BOUSQUET C, ZATELLI MC, MELMED S: Direct regulation of pituitary proopiomelanocortin by STAT3 provides a novel mechanism for immuno-neuroendocrine interfacing. J. Clin. Invest. (2000) 106:1417–1425.
   PubMedGoogle Scholar
• AUERNHAMMER CJ, MELMED S: Leukemia-inhibitory factor-neuroimmune modulator of endocrine function. Endocr. Rev. (2000) 21(3):313–345.
   PubMed Web of Science ®Google Scholar
• •Reviews the transcriptional regulation of ACTH biosynthesis, focusing on the signal transduction pathway of leukaemia-inhibitory factor.
   Google Scholar
• ARZT E, STELZER G, RENNER U, LANGE M, MULLER OA, STALLA GK: Interleukin-2 and interleukin-2 receptor expression in human corticotrophic adenoma and murine pituitary cell cultures. J Clin. Invest. (1992) 90:1944–1951.
   PubMedGoogle Scholar
• ARZT E, BURIC R, STELZER Get al.: Interleukin involvement in anterior pituitary cell growth regulation: effects of IL-2 and IL-6. Endocrinology (1993) 132:459–467.
   Google Scholar
• DE HERDER WW, HOFLAND LJ, USDIN TB et al.: Food-dependent Cushing's syndrome resulting from abundant expression of gastric inhibitory polypeptide receptors in adrenal adenoma cells. J Clin. Endocrinol. Metab. (1996) 81(9):3168–3172.
   PubMed Web of Science ®Google Scholar
• LACROIX A, N'DIAYE N, MIRCESCU H, TREMB LAY J, HAMET P: The diversity of abnormal hormone receptors in adrenal Cushing's syndrome allows novel pharmacological therapies. Braz. J Med. Biol. Res. (2000) 33(10):1201–1209.
   PubMedGoogle Scholar
• GROUSSIN L, PERLEMOINE K, CONTESSE V et aL: The ectopic expression of the gastric inhibitory polypeptide receptor is frequent in adrenocorticotropin-independent bilateral macronodular adrenal hyperplasia, but rare in unilateral tumors. J. Clin. Endocrinol. Metab. (2002) 87(5):1980–1985.
   PubMedGoogle Scholar
• ENGLER D, REDEI E, KOLA I: The corticotropin-release inhibitory factor hypothesis: a review of the evidence for the existence of inhibitory as well as stimulatory hypophysiotropic regulation of adrenocorticotropin secretion and biosynthesis. Endocr. Rev. (1999) 20(4):460–500.
   PubMedGoogle Scholar
• GIRALDI FP, CAVAGNINI F: Corticotropin-releasing hormone is produced by rat corticotropes and modulates ACTH secretion in a paracrine/autocrine fashion. J. Clin. Invest. (1998) 101(11):2478–2484.
   PubMedGoogle Scholar
• CHILDS GV, ROUGEAU D, UNABIA G: Corticotropin-releasing hormone and epidermal growth factor: mitogens for anterior pituitary corticotropes. Endocrinology (1995) 136:1595–1602.
   PubMedGoogle Scholar
• BRADBURY MJ, MCBURNIE MI, DENTON DA, LEE KF, VALE WW: Modulation of urocortin-induced hypophagia and weight loss by corticotropin-releasing factor receptor 1 deficiency in mice. Endocrinology (2000) 141(8):2715–2724.
   PubMedGoogle Scholar
• CULLEN MJ, LING N, FOSTER AC, PELLEYMOUNTER MA: Urocortin, corticotropin releasing factor-2 receptors and energy balance. Endocrinology (2001) 142(3):992–999.
   PubMedGoogle Scholar
• LUTON JP, MAHOUDEAU JA, BOUCHARD P et al.: Treatment of Cushing's disease by O,p'DDD. Survey of 62 cases. N Engl. J Med. (1979) 300(9):459–464.
   Google Scholar
• LUBITZ JA, FREEMAN L, OKUN R: Mitotane use in inoperable adrenal cortical carcinoma. JAMA (1973) 223(10):1109–1112.
   PubMedGoogle Scholar
• CIZZA G, CHROUSOS GP: Adrenocorticotrophic hormone-dependent Cushing's syndrome. Cancer Treat. Res. (1997) 89:25–40.
   PubMedGoogle Scholar
• CHU JW, MATTHIAS DF, BELANOFF J, SCHATZBERG A, HOFFMAN AR, FELDMAN D: Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). J Clin. Endocrinol. Metab. (2001) 86(8):3568–3573.
   PubMed Web of Science ®Google Scholar
• BERTAGNA X, BERTAGNA C, LAUDAT MH, HUSSON JM, GIRARD F, LUTON JP: Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing's syndrome. J. Clin. Endocrinol. Metab. (1986) 63(3):639–643.
   PubMedGoogle Scholar
• BERTAGNA X, BASIN C, PICARD F et al.:Peripheral antiglucocorticoid action of RU 486 in man. Clin. Endocrinol. (1988) 28(5):537–541.
   PubMedGoogle Scholar
• WOLKOWITZ OM, REUS VI: Treatment of depression with antiglucocorticoid drugs. Psychosom. Med. (1999) 61(5):698–711.
   PubMed Web of Science ®Google Scholar
• SONINO N, BOSCARO M, MEROLA G, MANTERO F: Prolonged treatment of Cushing's disease by ketoconazole. j Clin. Endocrinol. Metab. (1985) 61(4):718–722.
   PubMedGoogle Scholar
• STALLA GK, STALLA J, LOEFFLER JP, VON WERDER K, MULLER OA: Pharmacological modulation of CRH-stimulated ACTH secretion by ketoconazole. Horm. Metab. Res. Suppl. (1987) 16:31–36.
   PubMedGoogle Scholar
• STALLA GK, STALLA J, HUBER M et al.: Ketoconazole inhibits corticotropic cell function in vitro. Endocrinology (1988) 122(2):618–623.
   PubMed Web of Science ®Google Scholar
• STALLA GK, STALLA J, VON WERDER K et al.: Nitroimidazole derivatives inhibit anterior pituitary cell function apparently by a direct effect on the catalytic subunit of the adenylate cyclase holoenzyme. Endocrinology (1989) 125(2):699–706.
   Google Scholar
• ERIKSSON B, OBERG K: Summing up 15 years of somatostatin analog therapy in neuroendocrine tumours: future outlook. Ann. Oncol. (1999) 10\(Supp12):31–38.
   Google Scholar
• LAMBERTS SW, KRENNING FP, REUBI JC: The role of somatostatin and its analogues in the diagnosis and treatment of tumours. Endocr. Rev. (1991) 12:450–482.
   PubMed Web of Science ®Google Scholar
• VON WERDER K, MULLER OA, STALLA GK: Somatostatin analogues in ectopic corticotropin production. Metabolism (1996) 45(8 Suppl 1):129–131.
   Google Scholar
• DE HERDER WW, VAN DER LELY AJ, LAMBERTS SW: Somatostatin analogue treatment of neuroendocrine tumours. Postgr. Med. J. (1996) 72(849):403–408.
   PubMedGoogle Scholar
• GREENMAN Y, MELMED S: Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumours. J Clin. Endocrinol. Metab. (1994) 78:398–403.
   PubMed Web of Science ®Google Scholar
• HOFLAND LJ, VISSER-WISSELAAR HA, LAMBERTS SW: Somatostatin analogues: clinical application in relation to human somatostatin receptor subtypes. Biochem. Pharmacol. (1995) 50:287–297.
   PubMed Web of Science ®Google Scholar
• MEZEY E, HUNYADY B, MITRAS et al.: Cell specific expression of the sst2A and sst5 somatostatin receptors in the rat anterior pituitary. Endocrinology (1998) 139:414–419.
   PubMed Web of Science ®Google Scholar
• MERCADO-ASIS LB, YASUDA K, MURAYAMA M, MUNE T, MORITA H, MIURA K: Beneficial effects of high daily dose bromocriptine treatment in Cushing's disease. Endocrinol. Jpn. (1992) 39(4):385–395.
   PubMedGoogle Scholar
• BERWAERTS J, VERHELST J, MAHLER C, ABS R: Cushing's syndrome in pregnancy treated by ketoconazole: case report and review of the literature. Gynecol. Endocrinol. (1999) 13(3):175–182.
   PubMed Web of Science ®Google Scholar
• ISHIBASHI M, YAMAJI T: Direct effects of thyrotropin-releasing hormone, cyproheptadine, and dopamine on adrenocorticotropin secretion from human corticotroph adenoma cells in vitro. J Clin. Invest. (1981) 68(4):1018–1027.
   PubMed Web of Science ®Google Scholar
• HOLLSTEIN M, SIDRANSKY D, VOGELSTEIN B, HARRIS CC: p53 Mutations in human cancers. Science (1991) 253:49–53.
   PubMed Web of Science ®Google Scholar
• HARVEY M, VOGEL H, LEE EY, BRADLEY A, DONEHOWER LA: Mice deficient in bothp53 and Rb develop tumours primarily of endocrine origin. Cancer Res. (1995) 55:1146–1151.
   PubMed Web of Science ®Google Scholar
• JACKS T, FAZELI A, SCHMITT EM, BRONSON RT, GOODELL MA, WEINBERG RA: Effects of an Rb mutation in the mouse. Nature (1992) 359:295–300.
   PubMed Web of Science ®Google Scholar
• THAPAR K, SCHEITHAUER BW, KOVACS K, PERNICONE PJ, LAWS ER Jr: p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumour growth fractions. Neurosurgery (1996) 38:763–770.
   Google Scholar
• BUCKLEY N, BATES AS, BROOME JC et al.: P53 protein accumulates in Cushings adenomas and invasive non- functional adenomas. J Clin. Endocrinol. Metab. (1994) 79(5): 1513–1516.
   PubMedGoogle Scholar
• KONTOGEORGOS G, KAPRANOS N, THODOU E, SAMBAZIOTIS D, TSAGARAKIS S: Immunocytochemical accumulation ofp53 in corticotroph adenomas: relationship with heat shock proteins and apoptosis. Pituitary. (1999) 1:207–212.
   PubMedGoogle Scholar
• FERO ML, RIVKIN M, TASCH M et al.: A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility inp27(Kip1)-deficient mice. Cell (1996) 85:733–744.
   PubMed Web of Science ®Google Scholar
• NAKAYAMA K, ISHIDA N, SHIRANE M et al.: Mice lacking p27(Kipl) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumours. Cell (1996) 85:707–720.
   PubMed Web of Science ®Google Scholar
• FERO ML, RANDEL E, GURLEY KE, ROBERTS JM, KEMP CJ: The murine gene p27Kipl is haplo-insufficient for tumour suppression. Nature (1998) 396:177–180.
   PubMed Web of Science ®Google Scholar
• IKEDA H, YOSHIMOTO T, SHIDA N: Molecular analysis of p21 and p27 genes in human pituitary adenomas. Br. J. Cancer (1997) 76:1119–1123.
   PubMed Web of Science ®Google Scholar
• DAHIA PL, AGUIAR RC, HONEGGER J et al.: Mutation and expression analysis of the p27/kipl gene in corticotrophin- secreting tumours. Oncogene (1998) 16:69–76.
   PubMed Web of Science ®Google Scholar
• TAKEUCHI S, KOEFFLER HP, HINTON DR, MIYOSHI I, MELMED S, SHIMON I: Mutation and expression analysis of the cyclin-dependent kinase inhibitor gene p27/Kipl in pituitary tumours. J Endocrinol. (1998) 157:337–341.
   PubMedGoogle Scholar
• BAMBERGER CM, FEHN M, BAMBERGER AM et al.: Reduced expression levels of the cell-cycle inhibitor p27Kipl in human pituitary adenomas. Eur. J. Endocrinol. (1999) 140:250–255.
   PubMed Web of Science ®Google Scholar
• LIDHAR K, KORBONITS M, JORDAN S et al.: Low expression of the cell cycle inhibitorp27Kipl in normal corticotroph cells, corticotroph tumours, and malignant pituitary tumours]. Clin. Endocrinol. Metab. (1999) 84:3823–3830.
   Google Scholar
• •Important article on the expression of cell cycle regulatory proteins in ACTH-secreting tumour cells.
   Google Scholar
• SPENGLER D., VILLALBA M, HOFFMANN A et al.: Regulation of apoptosis and cell cycle arrest by Zacl, a novel zinc finger protein expressed in the pituitary gland and the brain. EMBOJ. (1997) 16:2814–2825.
   Google Scholar
• PAGOTTO U, ARZBERGER T, GIANT E et al.: Inhibition of Zacl, a new gene differentially expressed in the anterior pituitary, increases cell proliferation. Endocrinology (1999) 140:987–996.
   PubMed Web of Science ®Google Scholar
• THERRIEN M, DROUIN J: Pituitary pro-opiomelanocortin gene expression requires synergistic interactions of several regulatory elements. Mol. Cell. Biol. (1991) 11:3492–3503.
   PubMedGoogle Scholar
• ••Detailed analysis of the POMC promotor,providing clues on the regulation of ACTH biosythesis.
   Google Scholar
• PHILIPS A, LESAGE S, GINGRAS R et al.: Novel dimeric Nur77 signalling mechanism in endocrine and lymphoid cells. Mol. Cell. Biol. (1997) 17:5946–5951.
   PubMed Web of Science ®Google Scholar
• KOVALOVSKY D, REFOJO D, LIBERMAN AC et aL Activation and induction of nur77/nurrl in corticotrophs by CRH/cAMP: involvement of calcium, protein kinase A, and MAPK pathways. Mol. Endocrinol. (2002) 16(7):1638–1651.
   PubMedGoogle Scholar
• ••Detailed analysis of the signal transductionpathway of CRH in ACTH-secreting cells.
   Google Scholar
• PEREIRA FA, TSAI MJ, TSAI SY: COUP TF orphan nuclear receptors in development and differentiation. Cell Mol. Lifi Sci. (2000) 57:1388–1398.
   PubMedGoogle Scholar
• PAEZ-PEREDA M, KOVALOVSKY D, HOPFNER U et al.: Retinoic acid prevents experimental Cushing syndrome. J. Clin. Invest. (2001) 108:1123–1131.
   PubMed Web of Science ®Google Scholar
• •Novel description of the inhibitory effects of retinoic acid on ACTH biosynthesis and ACTH-secreting tumour cell proliferation.
   Google Scholar
• WU Q, LI Y, LIU R et al.: Modulation of retinoic acid sensitivity in lung cancer cells through dynamic balance of orphan receptors nur77 and COUP-TF and their heterodimerization. EMBO J. (1997) 16:1656–1669.
   PubMed Web of Science ®Google Scholar
• KLIEWER SA, KAZUHIKO U, HEYMAN RA, MANGELSDORF DJ, DYCK JA, EVANS RM: Retinoid X receptor-COUP-TF interactions modulate retinoic acid signalling. Proc. Natl Acad. Sci. USA (1992) 89:1448–1452.
   PubMed Web of Science ®Google Scholar
• LOTAN R: Retinoids in cancer chemoprevention. FASEB J. (1996) 10:1031–1039.
   PubMed Web of Science ®Google Scholar